Pieces in Place for NCI-MATCH Trial at Sylvester Comprehensive Cancer Center
With key progress underway, patients at Sylvester Comprehensive Cancer Center will soon be able to enroll in the NCI-MATCH (Molecular Analysis for Therapy Choice) clinical trial. Announced June 1 at the annual meeting of the American Society of Clinical Oncology in Chicago, the landmark precision medicine trial seeks to determine whether targeted therapies will be effective in patients whose tumors have specific genetic abnormalities, regardless of their cancer type.
Brian Slomovitz, M.D., Director of Gynecologic Oncology at Sylvester, has been named Principal Investigator of the Sylvester arm of the nationwide study that was co-developed by the National Cancer Institute (NCI). An experienced leader of national clinical trials and a specialist in robotic surgery, and novel therapeutics for endometrial cancer and ovarian cancer, Slomovitz says final approval for the trial is expected soon and Sylvester will be enrolling patients this fall.
Additionally, a Precision Medicine Research Clinic will be opening at Sylvester, part of UHealth-University of Miami Health System, to further enhance the targeted treatment and research being conducted at the cancer center.
The study will incorporate more than 20 different study drugs or drug combinations, each targeting a specific gene mutation. Instead of prescribing a drug based on the tumor location, such as breast or lung, NCI-MATCH will determine each patient’s genetic abnormality and match that to the drug that will target the mutation in their tumor.
“For Sylvester patients with rare cancers that don’t respond to traditional therapies, we’re offering full genomic sequencing of their tumors to identify those common mutations,” said Slomovitz. “Those patients could be eligible for one of these trials that treats their cancer based on the mutation. That’s where precision medicine is taking us.”
“The NCI-MATCH trial has the potential to revolutionize cancer care,” said Stephen D. Nimer, M.D., Director of Sylvester. “As we conduct this trial, Sylvester researchers will continue studies to further identify more genetic drivers and develop more targeted therapies which will lead to better outcomes.”